CClinicalTrials.gg
CompletedNCT01382043Updated Mar 21, 2018

Angiographic and IVUS Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals (AIFSIDDES)

An observational study in Percutaneous Coronary Angioplasty, sponsored by Liuhuaqiao Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-21.

Sponsored by Liuhuaqiao Hospital · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
48
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The safety and efficacy of drug-eluting stents (DES) with a biocompatible polymer have been demonstrated in randomized clinical trials as well as in real world practice. Theoretically, a new DES with a biodegradable polymer should reduce the incidence of late in-stent thrombosis, however, the long-term safety and efficacy of these stents remains unknown. This study was aimed to compare the safety and efficacy of the Excel DES with a biodegradable polymer to the Endeavor DES with a biocompatible polymer in same individuals.

02

Conditions studied

  • Percutaneous Coronary Angioplasty

Keywords

  • percutaneous coronary angioplasty
  • zotarolimus-eluting stent
  • sirolimus-eluting stent
  • biodegradable polymer
  • biocompatible polymer
03

In context

Lead sponsor

Liuhuaqiao Hospital is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patiemts who underwent simultaneous implantation of one or more Endeavor stents and one or more Excel stents during the same index procedure and were evaluated with coronary angiography and intravascular ultrasound (IVUS) at least one year post-procedure.

Inclusion criteria

  • simultaneous implantation of one or more Endeavor stents and one or more Excel stents during the same index procedure
  • willing to be followed up with coronary angiography and intravascular ultrasound at least one year post-procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients were excluded from the study if they had more than two kinds of stents implanted or if the two study stents were implanted during separate interventional procedures or in coronary artery bridge vessel or restenotic lesions.
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
48 participants (actual)

Groups and cohorts

  • Endeavor Segment group
  • Excel Segment Group
06

Study locations

1 site
  • Liuhuaqiao Hospital
    Guangzhou, Guangdong 510010, China
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01382043
Lead sponsor
Liuhuaqiao Hospital
First posted
Jun 27, 2011
Start date
Jun 2009
Primary completion
Sep 2010
Completion
Jan 2011
Last update
Mar 21, 2018

Study contacts

Dingcheng Xiang, Dr.
principal investigator · Liuhuaqiao Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion